ZBH

ZBH

USD

Zimmer Biomet Holdings Inc. Common Stock

$103.180+3.170 (3.170%)

即時價格

Healthcare
醫療器材
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$100.010

最高

$103.690

最低

$99.455

交易量

9.20M

公司基本面

市值

20.4B

行業

醫療器材

國家

United States

交易統計

平均交易量

1.41M

交易所

NYQ

貨幣

USD

52週範圍

最低 $89.22當前 $103.180最高 $114.72

相關新聞

PR Newswire

Zimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the U.S. Food and Drug Administration (FDA) has ...

查看更多
Zimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System
Analyst Upgrades

Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Maintains $101 Price Target

Canaccord Genuity analyst Caitlin Roberts maintains Zimmer Biomet Holdings with a Hold and maintains $101 price target.

查看更多
Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Maintains $101 Price Target
PR Newswire

Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting bold innovations across ...

查看更多
Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting
Analyst Upgrades

BTIG Maintains Buy on Zimmer Biomet Holdings, Raises Price Target to $122

BTIG analyst Ryan Zimmerman maintains Zimmer Biomet Holdings with a Buy and raises the price target from $118 to $122.

查看更多
BTIG Maintains Buy on Zimmer Biomet Holdings, Raises Price Target to $122
PR Newswire

Zimmer Biomet Launches Two New Foot and Ankle Solutions for Complex Trauma Cases

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, a wholly owned subsidiary, today announced the...

查看更多
Zimmer Biomet Launches Two New Foot and Ankle Solutions for Complex Trauma Cases
Analyst Upgrades

Evercore ISI Group Maintains In-Line on Zimmer Biomet Holdings, Lowers Price Target to $104

Evercore ISI Group analyst Vijay Kumar maintains Zimmer Biomet Holdings with a In-Line and lowers the price target from $106 to $104.